New paper lays out problems of developing gene-edited GM crops
By Claire Robinson,
GM Watch
| 08. 30. 2023
Announcing the passing into law of the Genetic Technology Act, which removes regulatory safeguards around a whole subclass of GMOs, notably those produced using gene editing, the Westminster government breathlessly enthused that the UK had now joined “Argentina, the US, Australia and Japan”, which “have already enacted similar legislation, driving innovation on a global scale and helping fight the greatest challenges facing the world”.
I can’t pretend that GMWatch was waiting with bated breath for the “new GM”-based “innovation on a global scale” that was supposed to be pouring out of these countries, especially given the dismal performance and fate of the handful of gene-edited crops that they've released.
But the history of GM crops has settled into a pattern of hyped reports of supposed successes continuing for a good few years before they give way to sad tales of technology failure. So at this early stage of the “new GM” journey, we were expecting something reasonably upbeat about gene-edited GM crops from these deregulatory pioneering countries.
What we didn’t expect just yet is the catalogue of abject failure...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...